Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics (PLRX) has announced its participation in four major investor events in December 2024. The company will attend the Evercore 7th Annual HealthCONx Conference on December 3 and the Citi 2024 Global Healthcare Conference on December 4. At the Piper Sandler 36th Annual Healthcare Conference, key executives including CEO Bernard Coulie will participate in a fireside chat on November 5. Additionally, company officials will join a panel discussion on 'Differentiated Approaches for Pulmonary Diseases' at the Oppenheimer Movers in Rare Disease Summit on December 12.
The Piper Sandler fireside chat will be available via live webcast on Pliant's website Investor Relations page, with a replay accessible for 30 days after the event.
Pliant Therapeutics (PLRX) ha annunciato la sua partecipazione a quattro importanti eventi per investitori nel dicembre 2024. L'azienda sarà presente alla 7ª Conferenza Annuale HealthCONx di Evercore il 3 dicembre e alla Conferenza Globale sulla Salute di Citi 2024 il 4 dicembre. Alla 36ª Conferenza Annuale sulla Salute di Piper Sandler, i dirigenti chiave, tra cui il CEO Bernard Coulie, parteciperanno a una chat informale il 5 novembre. Inoltre, i rappresentanti dell'azienda parteciperanno a una tavola rotonda su 'Approcci Differenziati per le Malattie Polmonari' al Vertice Oppenheimer Movers in Rare Disease il 12 dicembre.
La chat informale di Piper Sandler sarà disponibile in diretta streaming sulla pagina delle Relazioni con gli Investitori del sito di Pliant, con una registrazione accessibile per 30 giorni dopo l'evento.
Pliant Therapeutics (PLRX) ha anunciado su participación en cuatro importantes eventos para inversores en diciembre de 2024. La empresa asistirá a la 7ª Conferencia Anual HealthCONx de Evercore el 3 de diciembre y a la Conferencia Global de Salud de Citi 2024 el 4 de diciembre. En la 36ª Conferencia Anual de Salud de Piper Sandler, ejecutivos clave, incluido el CEO Bernard Coulie, participarán en una charla informal el 5 de noviembre. Además, los funcionarios de la empresa se unirán a una discusión en panel sobre 'Enfoques Diferenciados para las Enfermedades Pulmonares' en la Cumbre Oppenheimer Movers en Enfermedad Rara el 12 de diciembre.
La charla informal de Piper Sandler estará disponible a través de una transmisión en vivo en la página de Relaciones con Inversores del sitio web de Pliant, con una repetición accesible durante 30 días después del evento.
Pliant Therapeutics (PLRX)는 2024년 12월에 열리는 네 개의 주요 투자자 행사에 참여할 예정이라고 발표했습니다. 이 회사는 12월 3일에 열리는 Evercore 제7회 연례 HealthCONx 컨퍼런스와 12월 4일에 열리는 Citi 2024 글로벌 헬스케어 컨퍼런스에 참석할 것입니다. Piper Sandler 제36회 연례 헬스케어 컨퍼런스에서 CEO Bernard Coulie를 포함한 주요 임원들이 11월 5일에 진행되는 화로 대화에 참여할 예정입니다. 또한, 회사 관계자들은 12월 12일에 열리는 Oppenheimer Movers in Rare Disease Summit에서 '호흡기 질환을 위한 차별화된 접근법'에 대한 패널 토론에 참석합니다.
Piper Sandler의 화로 대화는 Pliant의 웹사이트 투자자 관계 페이지에서 라이브 웹캐스트로 제공되며, 행사 후 30일 동안 다시 볼 수 있습니다.
Pliant Therapeutics (PLRX) a annoncé sa participation à quatre événements majeurs pour les investisseurs en décembre 2024. La société participera à la 7e Conférence Annuelle HealthCONx d'Evercore le 3 décembre et à la Conférence Globale de la Santé Citi 2024 le 4 décembre. Lors de la 36e Conférence Annuelle sur la Santé de Piper Sandler, des cadres clés, y compris le PDG Bernard Coulie, participeront à une discussion informelle le 5 novembre. De plus, des responsables de l'entreprise rejoindront une discussion en panel sur 'Approches Différenciées pour les Maladies Pulmonaires' lors du Sommet Oppenheimer Movers sur les Maladies Rares le 12 décembre.
La discussion informelle de Piper Sandler sera disponible en direct sur la page des Relations avec les Investisseurs du site web de Pliant, avec un replay accessible pendant 30 jours après l'événement.
Pliant Therapeutics (PLRX) hat seine Teilnahme an vier bedeutenden Investorenveranstaltungen im Dezember 2024 angekündigt. Das Unternehmen wird am 3. Dezember an der 7. jährlichen HealthCONx-Konferenz von Evercore und am 4. Dezember an der Citi 2024 Global Healthcare Conference teilnehmen. Bei der 36. jährlichen Healthcare-Konferenz von Piper Sandler werden wichtige Führungskräfte, darunter CEO Bernard Coulie, am 5. November an einem Kamin-Gespräch teilnehmen. Darüber hinaus werden Unternehmensvertreter am 12. Dezember an einer Podiumsdiskussion zum Thema 'Differenzierte Ansätze für Lungenkrankheiten' im Rahmen des Oppenheimer Movers in Rare Disease Summit teilnehmen.
Das Kamin-Gespräch von Piper Sandler wird über einen Live-Webcast auf der Investor-Relations-Seite der Pliant-Website verfügbar sein, mit einer Wiederholung, die 30 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following December investor events.
- Evercore 7th Annual HealthCONx Conference Members of Pliant’s senior management will meet with investors on Tuesday, December 3, 2024.
- Citi 2024 Global Healthcare Conference Members of Pliant’s senior management will meet with investors on Wednesday, December 4, 2024.
- Piper Sandler 36th Annual Healthcare Conference Bernard Coulie, M.D., Ph.D. Pliant’s President and Chief Executive Officer, Keith Cummings, M.D., Pliant’s Chief Financial Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat on Thursday, November 5, 2024, at 8:00 a.m. Eastern Time.
- Oppenheimer Movers in Rare Disease Summit Keith Cummings, M.D., and Éric Lefebvre, M.D., will participate in the panel discussion “Differentiated Approaches for Pulmonary Diseases” on Thursday, December 12, 2024, as part of an invitation-only event hosted by Oppenheimer.
Interested parties may access the live webcast of the Piper Sandler fireside chat by visiting the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com. Follow us on social media: X, LinkedIn, and Facebook.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
What investor conferences will Pliant Therapeutics (PLRX) attend in December 2024?
Will the Pliant Therapeutics (PLRX) Piper Sandler presentation be available online?
Which Pliant Therapeutics (PLRX) executives will participate in the Piper Sandler conference?
What panel will Pliant Therapeutics (PLRX) participate in at the Oppenheimer summit?
